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Abstract: The aim of this study was to investigate possible stress-associated disturbances in lipid
metabolism in mononuclear cells, mainly lymphocytes of patients with psoriasis vulgaris (Ps, n = 32)
or with psoriatic arthritis (PsA, n = 16) in respect to the healthy volunteers (n = 16). The results showed
disturbances in lipid metabolism of psoriatic patients reflected by different phospholipid profiles.
The levels of non-enzymatic lipid metabolites associated with oxidative stress 8-isoprostaglandin F2α
(8-isoPGF2α) and free 4-hydroxynonenal (4-HNE) were higher in PsA, although levels of 4-HNE-His
adducts were higher in Ps. In the case of the enzymatic metabolism of lipids, enhanced levels
of endocannabinoids were observed in both forms of psoriasis, while higher expression of their
receptors and activities of phospholipases were detected only in Ps. Moreover, cyclooxygenase-1
(COX-1) activity was enhanced only in Ps, but cyclooxygenase-2 (COX-2) was enhanced both in
Ps and PsA, generating higher levels of eicosanoids: prostaglandin E1 (PGE1), leukotriene B4
(LTB4), 13-hydroxyoctadecadienoic acid (13HODE), thromboxane B2 (TXB2). Surprisingly, some of
major eicosanoids 15-d-PGJ2 (15-deoxy-∆12,14-prostaglandin J2), 15-hydroxyeicosatetraenoic acid
(15-HETE) were elevated in Ps and reduced in PsA. The results of our study revealed changes in lipid
metabolism with enhancement of immune system-modulating mediators in psoriatic mononuclear
cells. Evaluating further differential stress responses in Ps and PsA affecting lipid metabolism and
immunity might be useful to improve the prevention and therapeutic treatments of psoriasis.
Keywords: lipid mediators; psoriasis vulgaris; psoriatic arthritis; lipid peroxidation products;
endocannabinoids; eicosanoids
1. Introduction
Psoriasis is a chronic autoimmune disease, the most common form of which is psoriasis vulgaris,
characterized by pathological interactions between immune cells, especially lymphocytes, and skin
cells, especially keratinocytes. In some patients, psoriasis is characterized by a more severe clinical
course, leading to the development of psoriatic arthritis [1]. The cause of the disease remains unknown,
although some genetic or environmental factors are associated with the development of psoriasis.
Thus, it has been observed that lymphocytes and the cytokines they produce, especially interferon γ
(IFNγ) and interleukin 17 (IL-17), affect other cells, leading to chronic inflammation and characteristic
symptoms such as cutaneous plaques in psoriasis or arthrosis and loss of movement in psoriatic arthritis.
Moreover, the pro-inflammatory phenotype of lymphocytes and other immune cells is observed not
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only locally in the skin or joints, but also in cells isolated from blood, which confirms that general
inflammation is present in psoriasis [2]. However, that can only partially explain the course of the
disease, still leaving many questions open in respect to the development of psoriasis or the transition of
one form to another. Recent studies on immunological diseases have revealed that their development
is often accompanied by oxidative stress and increased metabolism of phospholipids, suggesting that
both ROS and lipid mediators play important roles in the pathophysiology of psoriasis [3]. In psoriasis,
both systemic and local, oxidative stress and increased metabolism of phospholipids have been
demonstrated. Among immune-competent, inflammatory cells of psoriatic patients were observed
especially for granulocytes, which increasingly generate lipid peroxidation products, thus modulating
their inflammatory activities [4]. Furthermore, it has been shown that activation of lymphocytes is also
accompanied by the generation of large amounts of reactive oxygen species (ROS) that are important
mediators of cytokine-mediated redox biology [5]. Biological activities of ROS are related to their
ability to react with biomolecules, such as phospholipids, in particular polyunsaturated fatty acids
(PUFA), which leads to lipid peroxidation and generation of reactive aldehydes, e.g., 4-hydroxynonenal
(4-HNE), which is denoted also as a “second messenger of free radicals” [6].
In addition to lipid peroxidation, cellular phospholipids are also metabolized by enzymes,
the activities of which are increased in various inflammatory processes. The most important
enzymes involved in the generation of lipid mediators are phospholipases, cyclooxygenases
(COXs), and lipoxygenases (LOXs) [7]. During this process phospholipases begin biosynthesis
of endocannabinoids among which the best known are 2-acyloglycerol (2-AG) and anandamide (AEA).
Enhanced levels of them are observed in inflammatory diseases like osteoarthritis or systemic lupus
erythematosus [8,9]. Endocannabinoids affect cells mostly by interactions with their receptors,
cannabinoid receptors (CB1 and CB2). It is known that activation of CB2 receptor results in
anti-inflammatory and anti-oxidative regulation, while activation of CB1 shows pro-inflammatory
and pro-oxidative activity [10]. In addition, endocannabinoids have been found to be involved in
the development of psoriatic comorbidities. Therefore, it can be assumed that disturbances of the
endocannabinoid system may also play a significant role in the course of psoriasis.
Moreover, recent studies suggest, that effect of endocannabinoids action is also dependent on the
action of their metabolites [11]. Anandamide is metabolized into arachidonic acid which together with
arachidonic acid revealed from phospholipids is further metabolized into eicosanoids by (COXs) and
LOX. Among cyclooxygenases COX-2 is believed to be the main enzyme responsible for generation of
active lipid mediators during inflammation [12], while arachidonic acid is also a substrate to synthesis
of thromboxanes, leukotrienes, and prostaglandins [13].
Since lipid mediators are commonly observed in autoimmune diseases, they are constantly gaining
increased attention among researchers focused on autoimmune diseases. Lipid mediators might
accordingly be important for studies on diseases with poorly understood pathophysiology and without
effective therapy, like psoriasis. As such, the aim of this study was to investigate oxidative lipid
modifications in mononuclear cells, mainly lymphocytes isolated from patients suffering from psoriasis
vulgaris (Ps) or psoriatic arthritis (PsA).
2. Results
Phospholipids that could distinguish patients with psoriasis vulgaris and psoriatic arthritis were
selected by use of multivariate statistics. Twenty phospholipid species with variable importance in
projection (VIP ≥ 1) were selected, which were driving the separation of examined groups. Principal
component analysis (PCA) model (Figure 1) was constructed to check classification of each group.
The complete data set with the log transformed and auto-scaled phospholipid variables was used
to carry out the analysis. The PCA model, on which each point represents an individual sample,
showed that the group of healthy subjects was clearly separated from the patients groups, while the
separation between both types of psoriasis almost did not occur. The model captured 78.1% of the total
variance. The variation in the variables is represented by two principal components of PC1 (57.7%)
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versus PC2 (14.7%). It is highly probable that PC1 is associated with the age, while PC2 indicates a
positive correlation with disease state. It was observed that the samples from both groups of psoriatic
patients showed positive values for PC2, whereas those from healthy subjects presented negative
values. Finally, we used partial least squares-discriminate analysis (PLS-DA) (Figure S1) and VIP for
estimation of the importance of each phospholipid species which drove the separation of the examined
groups (Table 1).
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Figure 1. Principal co ponent analysis (PCA) plot of the phospholipid species relative abundance
determined by HILIC-LC- S in lymphocytes of patient with psoriasis vulgaris (n = 10) and psoriatic
arthritis (n = 10) as well as healthy subjects (n = 10); 95% confidential intervals are indicated by
shaded area.
Table 1 shows the details of these species that belong to lysophosphatidylcholine (LPC),
phosphatidylcholine (PC), phosphatidylinositol (PI), and sphingomyelin (SM) classes. Two
phosphatidylcholines containing eicosatrienoic (20:3) and docosadienoic (22:2) acid, namely
PC(20:0/22:2), and PC(20:3/24:0), had the highest VIP scores. In general, PC was down-regulated
in patients of both types of psoriasis while two SM species, containing tetracosadienoic (24:2) and
docosaenoic acid (22:1), respectively, were up-regulated. Other phospholipid species that were changed
in the course of both forms of psoriasis belong to the PI class. PI species were down-regulated in
both groups of patients with exception of PI(24:0/24:0), PI(24:0/24:1), and PI(18:0/22:0), which were
highly up-regulated. Important to notice is that PI species containing arachidonic and linoleic acid,
namely PI(16:0/20:4), PI(18:0/20:4), and PI(18:2/22:0) were significantly down-regulated in both groups
of psoriatic patients in comparison to healthy subjects. Moreover, most of PI species were found to be
more altered in PsA patients than those with Ps. LPC species with the score > 1, namely LPC(16:0) and
LPC(18:0), were found to be highly up-regulated in psoriasis in comparison to healthy subjects. Hence,
these two LPC species were mostly responsible for the differentiation of both types of psoriasis from
healthy subjects (Table 1).
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Table 1. Changes in mononuclear cells top 20 phospholipid species with VIP score greater than one comparing the healthy subjects (C; n = 10) to psoriasis vulgaris
(n = 10) and psoriasis arthritis (n = 10) groups of patients; ns, not statistically significant.
m/z RT ID Composition VIP
Log2 (Fold-Change)
Control vs.
Psoriasis
Vulgaris
p Value
Control vs.
Psoriatic
Arthritis
p Value
Psoriasis Vulgaris
vs. Psoriatic
Arthritis
p Value
928.6940 18.31 PC(42:2) PC(20:0/22:2) 1.97 0.63 2.34 × 10−5 0.34 1.17 × 10−3 0.29 ns
954.7113 18.12 PC(44:3) PC(20:3/24:0) 1.89 0.54 3.76 × 10−5 0.26 2.84 × 10−3 0.29 ns
917.6085 3.47 PI(40:2) PI(18:2/22:0) 1.57 0.68 1.13 × 10−5 0.90 1.81 × 10−8 −0.21 ns
915.5954 3.47 PI(40:3) PI(18:0/22:3) 1.57 0.75 1.13 × 10−5 0.97 3.91 × 10−8 −0.21 ns
1033.7629 3.90 PI(48:0) PI(24:0/24:0) 1.52 −1.06 5.81 × 10−4 −0.85 2.06 × 10−3 −0.21 ns
857.6755 18.16 SM(d41:2) SM(d17:0/24:2) 1.51 −0.50 5.81 × 10−4 −0.26 3.36 × 10−2 −0.23 ns
868.6052 16.49 PC(38:4) PC(18:0/20:4) 1.47 −0.181 2.00 × 10−3 0.31 1.66 × 10−2 0.26 ns
1031.7489 3.90 PI(48:1) PI(24:0/24:1) 1.44 −1.64 1.03 × 10−3 −1.43 1.93 × 10−3 −0.2109 ns
857.5159 3.85 PI(36:4) PI(16:0/20:4) 1.39 0.68 5.81 × 10−4 0.89 1.26 × 10−5 −0.21 ns
840.5732 16.71 PC(36:4) PC(16:0/20:4) 1.39 0.56 3.51 × 10−3 0.31 3.00 × 10−2 0.25 ns
896.6372 16.37 PC(40:4) PC(18:0/22:4) 1.38 0.42 4.04 × 10−3 0.14 ns 0.27 ns
909.5490 3.84 PI(40:6) PI(18:2/22:4) 1.38 0.61 3.33 × 10−4 0.82 2.76 × 10−6 −0.21 ns
792.5746 17.39 PC(32:0) PC(16:0/16:0) 1.37 0.54 4.04 × 10−3 0.28 ns 0.25 ns
921.6399 3.99 PI(40:0) PI(18:0/22:0) 1.36 −1.89 1.63 × 10−3 −1.68 3.02 × 10−3 −0.21 ns
885.5472 3.83 PI(38:4) PI(18:0/20:4) 1.35 0.57 2.61 × 10−4 −0.26 ns −0.21 ns
554.3463 20.37 LPC(16:0) 1.33 −1.77 5.81 × 10−4 −2.6 3.53 × 10−6 0.83 ns
582.3771 20.10 LPC(18:0) 1.31 −1.50 3.32 × 10−5 −2.3 7.98 × 10−8 0.83 ns
894.6222 16.40 PC(40:5) PC(18:1/22:4) 1.30 0.50 4.72 × 10−3 0.80 ns 0.26 ns
843.6591 18.25 SM(d40:2) SM(d18:1/22:1) 1.26 −0.50 4.70 × 10−3 −0.20 ns −0.29 ns
911.5644 3.84 PI(40:5) PI(18:1/20:4) 1.26 0.59 1.63 × 10−3 0.24 4.78 × 10−5 −0.21 ns
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It is often assumed that the reduced level of PUFAs is related to their ROS-dependent and
enzyme-dependent metabolism. Consequently, the elevated levels of lipid peroxidation products
belonging to compounds generated during PUFAs’ oxidative fragmentation, such as 4-HNE, as well
as to compounds generated during PUFAs oxidative cyclisation, such as 8-iso prostaglandin F2α
(8-isoPGF2α), was observed, in particular in patients with PsA (Figure 2).
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Figure 2. The level of phospholipid oxidative modifications products and of 4-HNE-protein adducts
in mononuclear cells of healthy peoples (n = 16) and patients with psoriasis vulgaris (n = 32) and
psoriatic arthritis (n = 16). 8-isoPGF2α, F2α-8-isoprostaglandin; 4-HNE, 4-hydroxynonenal. Data points
represent the mean ± SD; a, significantly different from healthy subject, p < 0.05; x, significantly different
from patients with psoriasis vulgaris, p < 0.05.
That might indeed be that case with psoriatic patients because their observed decrease of PUFAs
was associated by e hanced activities of the enzymes metabolizing lipids including phospholipases
(PLA2 and PAF-AH), as well as of cyclooxygenas 1 (COX1) a d cyclooxygenase2 (COX2), especially
in Ps (Figure 3).
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Figure 3. The activity of the enzymes involved in phospholipid metabolism in mononuclear cells of
patients psoriasis vulgaris (n = 32) and p oriatic arthritis (n = 16) as well as healthy subjects ( = 16). PLA2,
phosholipase A2; PAF-AF, platelet-activating factor acetylhydrolase; COX, cyclooxygena es. Data points
represent the mean ± SD; a, significantly different from he lthy subject, p < 0.05; x, significantly different
from patie with psoriasis vulgaris, p < 0.05.
It is likely that increased activity of the above listed enzymes promoted generation of
endocannabinoids. The levels of anandamide and LEA increased more in mononuclear cells of patients
with PsA, while the concentration of 2-AG, 2-LG (2-linoleoylglycerol), and OEA (oleoylethanolamide)
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was higher in patients with Ps (Table 2). An elevated level of endocannabinoids was observed
despite the increased activity of enzymes degrading them (FAAH—fatty acid amide hydrolase and
MAGL—monoacylglycerol lipase), especially in mononuclear cells of patients with Ps (Table 2).
Table 2. The level of endocannabinoids and enzymes degrading them (FAAH and MAGL) in
mononuclear cells of patients with psoriasis vulgaris (n = 32) and psoriatic arthritis (n = 16)
Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-LG, 2-linoleoylglycerol; AEA, anandamide; FAAH,
fatty acid amide hydrolase; LEA, dihomo-γ-linolenoylethanolamine; MAGL, monoacylglycerol lipase;
OEA, oleoylethanolamide. Data points represent the mean ± SD; a, significantly different from healthy
subject, p < 0.05; x, significantly different from patients with Ps, p < 0.05.
Analyzed Parameters Healthy Subjects Psoriasis Vulgaris Psoriatic Arthritis
AEA
(pmol/mg protein) 0.17 ± 0.02 0.19 ± 0.03a 0.23 ± 0.04ax
2-AG
(pmol/mg protein) 1.87 ± 0.18 3.24 ± 0.45a 2.78 ± 0.37ax
2-LG
(pmol/mg protein) 5.59 ± 0.87 7.92 ± 0.99a 7.41 ± 0.93a
LEA
(pmol/mg protein) 0.79 ± 0.08 0.94 ± 0.15a 1.17 ± 0.15ax
OEA
(pmol/mg protein) 0.33 ± 0.05 0.47 ± 0.07a 0.36 ± 0.05a
FAAH
(pmol/min/mg protein) 170 ± 16 219 ± 28a 242 ± 31ax
MAGL
(pmol/min/mg protein) 55 ± 6 75 ± 10a 83 ± 14ax
Increased level of endocannabinoids resulted in enhanced expression of cannabinoids receptors
(CB1 and CB2), as well as other receptors activated also by endocannabinoids (GPR55 and TRPV1) in
Ps and decreased expression of these receptors in PsA (Figure 4). Products of phospholipid metabolism
including endocannabinoids, but also fatty acids and eicosanoids, are ligands of nuclear peroxisome
proliferator-activated receptors (PPARα, PPARγ, PPARδ). A significant increase in the expression of
these receptors was observed in mononuclear cells obtained from patients with Ps, while it was only
moderately raised in mononuclear cells of patients with PsA (Figure 4).
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Figure 4. The expression of receptors involved in phospholipid metabolism in mononuclear cells of
patients with psoriasis vulgaris (n = 16) and psoriatic arthritis (n = 8) and healthy peoples (n = 8).
CB1, CB2, cannabinoid receptors; GRP55, G protein-coupled receptor 55; TRPV, the transient receptor
potential cation channel subfamily V member 1; PPAR, peroxisome proliferator-activated receptor.
Data points represent the mean ± SD; a, significantly different from healthy subjects, p < 0.05; x,
significantly different from patients with psoriasis vulgaris, p < 0.05.
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Increased activity of PLA2 lead to the enhanced release of arachidonic acid, which is further
metabolized (mainly by cyclooxygenases and lipoxygenases) into another large group of active
lipid mediators, notably eicosanoids (Figure 5) Among them, pro-inflammatory factors, such as
13-hydroxyoctadecadienoic acid (13-HODE) and leukotriene B4 (LTB4) levels, were increased in both
forms of the disease. In particular LTB4 level increased dramatically in psoriasis, especially in Ps.
In addition, thromboxane B2 (TxB2), (metabolite of pro-inflammatory thromboxane A2 (TxA2) level
was increased in Ps, which might be related to the activities of cyclooxygenases. The analysis
of anti-inflammatory mediators revealed decreased levels of 15-deoxy-∆12,14-prostaglandin J2
(15-d-PGJ2) in patients with Ps, while 15-hydroxyeicosatetraenoic acid (15-HETE) levels were slightly,
but significantly, increased in Ps, and prostaglandin E1 (PGE1) levels were increased both in Ps
(four-fold) and in PsA (two-fold).
Since psoriasis is known to be associated with inflammation, basic pro-inflammatory and
anti-inflammatory parameters were examined (Figure 6). The levels of pro-inflammatory cytokine IL-2
was increased above normal in mononuclear cells of both forms of psoriasis, while anti-inflammatory
IL-10 levels were not changed in psoriatic patients.
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3. Discussion
Psoriasis is a complex inflammatory disease associated with increased activation of lymphocytes [14],
which leads to the generation of pro-inflammatory cytokines and to pro-oxidative processes causing
oxidative stress [3]. The results of our study confirm the onset of oxidative stress in psoriasis, which is,
in particular in PsA, manifested by changes in the metabolism of phospholipids in mononuclear cells,
mainly containing lymphocytes, thus offering better understanding of the diseases, due to differentially
expressed changes in lipid metabolism between Ps and PsA examined mononuclear cells.
The main source of ROS in cells are usually mitochondria whose respiratory chain may be disrupted
by various factors, including phospholipids’ metabolites, such as endocannabinoids, the levels of which
were, in the current study, found to be increased in the mononuclear cells of psoriatic patients. It is
known that the main endocannabinoids, AEA and 2-AG, may stimulate the function of mitochondria,
including the production of hydrogen peroxide by enhanced entry of calcium ions into the cell [15].
In addition, activation of cannabinoid receptors (CB1), caused by endocannabinoids, which was, in our
study, also found to be increased in mononuclear cells of psoriatic patients, may promote oxidative
stress by enhanced inflammation, e.g., through NOS stimulation leading to increased generation of
superoxide and nitric oxide [16]. In favor of this possibility are increased activities of cytosolic NADPH
and xanthine oxidases in granulocytes and in plasma of patients with psoriasis, in particular if obtained
from patients with PsA [4]. Such changes were accompanied by disturbances in the antioxidant system,
which was spread in a stress-response manner lowering the level/activity of cellular antioxidants.
Similarly, redox imbalance and inflammation observed in psoriatic patients were, in the current
study, associated with changes in ROS-dependent and enzyme-dependent phospholipid metabolism
of mononuclear cells affecting especially PUFAs, which are lipid species the most sensitive to the ROS
attack causing lipid peroxidation. Different phospholipid species, including phosphatidylcholines
and phosphatidylinositols containing linoleic, arachidonic, eicosatetraenoic and docosadienoic acids,
in particular, were down-regulated in mononuclear cells of psoriatic patients. Arachidonic acid and
linoleic acid are the major PUFAs, which are oxidized in a ROS-dependent manner to biologically-active
lipid mediators, including products of oxidative fragmentation (mainly α,β-unsaturated electrophilic
aldehydes, with 4-HNE as the most important one) and products of oxidative cyclisation (mainly
prostaglandin derivatives, such as 8-isoPGF2α) that further propagate oxidative damages altering
functional activities of the immune-competent cells [17]. The mechanism of 8-isoPGF2α action is based
on TNFα activation [18]. So far, increased levels of 8-isoPGF2α have been found in psoriatic patients’
serum [19] as well as in the skin cells [20] being accompanied by elevated TNFα expression [21].
However, 4-HNE is a more potent biomarker of lipid peroxidation, which is involved in complex
regulation of inflammatory and immunological responses [6]. The increased levels of the free 4-HNE
were observed in our study especially in the mononuclear cells of PsA patients. Opposite to that,
the levels of histidine-bound protein adducts of 4-HNE were higher in examined cells of patients
with Ps indicating differential metabolic and scavenging pathways for this “second messenger of
free radicals” in Ps and in PsA patients. It is known that unsaturated aldehydes, such as 4-HNE,
have a strong affinity for covalently linking with nucleophilic amino and thiol groups of biomolecules,
including proteins and glutathione (GSH) [17]. Since the thiol groups of protein cysteine residues act
as redox switches controlling cell signaling and metabolism [22], versatile interactions of cysteine with
signaling molecules, such as 4-HNE, can selectively modulate protein functions [23]. Complementary
to that, modifications of protein residues, not only cysteine but also histidine or lysine, may lead to
disturbances of biological functions of modified proteins and their translocation to the cell membrane
and activation of protein G [24–26]. Our findings suggest that such protein adducts may participate
in enhanced expression of protein G-coupled receptors (including cannabinoid receptors), as was
observed in this study in mononuclear cells of psoriatic patients.
The cellular metabolism of phospholipids, independent of ROS, also includes enzymatic reactions
leading to the generation of endocannabinoids dependent on the activity of phospholipases [27].
Despite the increased activity of endocannabinoid-metabolizing enzymes (FAAH and MAGL),
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endocannabinoid levels were elevated in our patients. The main endocannabinoids, anandamide and
2-arachidonoylglycerol (2-AG), participate in the modulation of inflammation and redox balance mainly
through the activation of cannabinoid receptors [28]. Crosstalk between ROS and endocannabinoids
has been proven in various diseases [27], but so far not in patients with psoriasis, as was done for the
first time in the present study.
In addition, inflammation is associated with increased expression of lymphocyte receptors: GPR55
and TRPV1 [29,30]. According to in vitro studies endocannabinoids themselves may also act as
anti-inflammatory agents by promoting the Th2 cell phenotype and further inhibit the production
of pro-inflammatory cytokines by lymphocytes [31]. This may suggest that endocannabinoids are
generated, among others, to alleviate the inflammatory aspects of psoriasis. In fact, in the case of Ps
we observed a higher expression of endocannabinoid receptors but, surprisingly, in the case of PsA,
the expression of these receptors has been reduced, suggesting no cellular response to the regulatory
role of endocannabinoids. It is possible that the receptors or membrane protein G have been modified
by 4-HNE, which can explain also less pronounced increase of the soluble 4-HNE-protein adducts in
patients with PsA, who have otherwise higher levels of the free aldehyde than patients with Ps. In any
case, the disrupted immunosuppressive effect of endocannabinoids in PsA may be an important factor
differentiating the pathophysiology of both forms of psoriasis and may promote exacerbation of Ps
into the form of PsA.
Enzymatic degradation of endocannabinoids, with COXs participation in particular, plays a
critical role in the onset of the inflammatory cascade with the generation of different biologically-active
compounds, including eicosanoids [32]. Among them are various bioactive agents, such as
prostaglandins, thromboxanes, and leukotrienes, which can participate in the pathophysiology
of psoriasis. Eicosanoids may have opposite inflammatory effects and, thus, modulate skin disorders.
The results of this study revealed a significant increase in mononuclear cells of patients with psoriasis
TxB2, a stable metabolite of TxA2, which plays a pro-inflammatory role in imiquimod-induced psoriatic
dermatitis [33]. Additionally, elevated LTB4 levels may promote skin inflammation [34]. Inflammation
may also be modified by 15d-PGJ2, which is elevated in Ps, and which inhibits NFκB mediated
metabolic pathways by inhibiting IκB kinase (IKK) activity [35].
Another mechanism of interactions redox biology-lipid metabolism in the mononuclear cells
of psoriatic patients may be associated with the expression of nuclear receptors like peroxisome
proliferator-activated receptors—PPARs [36], whose forms: PPARα, PPARγ, and PPARδwere enhanced
in mononuclear cells of patients with psoriasis, particularly with Ps. Moreover, PUFAs, eicosanoids,
and endocannabinoids may be ligands of PPARs, which in B and T lymphocytes serve as important
regulators of the immune system as potential anti-inflammatory targets for PPAR ligands [37,38].
PPARα and PPARδ show antioxidant properties by suppressing enzymes involved in
ROS/RNS generation [39], while enhanced activation of PPARα may also prevent NFκB–dependent
inflammation [40]. The results obtained by the murine translation study indicated that PPARα
activation may be one of the protective mechanisms against progression of skin inflammation [41].
Additionally, the PPARδ promotes synthesis of antioxidants, such as thioredoxin, superoxide dismutase,
or heme oxygenase [42]. Thus, PPARδ enhanced expression seems to be an important antioxidative
mechanism in patients with Ps. The significant decrease in their expression observed in PsA confirms
that the lack of anti-stress protection against ROS leads to an increase the severity of this disease.
In addition, increased PPARγ expression, as discovered in this study, may be involved in reduction of
TNFα level, particularly in PsA [43].
4. Materials and Methods
4.1. Materials
Blood samples were collected from 32 patients with psoriasis vulgaris (Ps) (16 females, 16 men;
mean age 38) and 16 patients with psoriatic arthritis (seven females, nine men; mean age 35).
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Only patients with psoriasis vulgaris for at least six months and characterized by at least 10% of the
total body surface affected by the disease were included in the study (the median of their psoriasis
surface index and severity index (PASI) was 21, with a range of 15–25). Patients with psoriatic arthritis
(PsA) were diagnosed on the basis of a questionnaire CASPAR (ClASsification criteria for Psoriatic
Arthritis). All participants gave their informed consent for inclusion in the research. The research
was carried out in accordance with the Helsinki Declaration, and the protocol was approved by the
Local Bioethics Commission at the Medical University of Białystok (Poland), no. R-I-002/289/2017
(2017.09.28). People receiving topical or oral medications during the four weeks before the study and
comorbidities/smoking or alcohol abuse were excluded from examinations.
Blood was collected into tubes with ethylenediaminetetraacetic acid as an anti-coagulant and
butylhydroxytoluene as an antioxidant. Density gradient centrifugation (Gradisol L, 300 g, 25 min) was
used to obtain mononuclear cells mainly containing lymphocytes fraction from blood. This fraction was
washed in phosphate-buffered saline (PBS), then resuspended in PBS containing proteases inhibitors
mix. Purity of the cells has been examined microscopically (Nikon Eclipse Ti, Nikon Instruments
Inc., Melville, NY, USA). Isolated fractions were lysed by sonification on ice and stored at −80 ◦C
before further analysis. All obtained parameters are expressed per mg of protein (protein levels were
examined using Bradford method [44]).
4.2. Methods
4.2.1. Phospholipid Profile Estimation
Mononuclear cells from ten patients with Ps, ten patients with PsA (5f + 5m) and ten healthy
subjects (5f + 5m) were used to estimate phospholipid profile of each group. Total lipids from all
samples were extracted by the modified Bligh and Dyer method [45]. The total amount of phospholipids
(PL) was calculated by using a phosphorus assay, performed according to Bartlett and Lewis [46].
Hydrophilic interaction chromatography liquid chromatography-mass spectrometry (HILIC-LC)-MS,
performed on an Agilent 1290 ultra-performance liquid chromatography (UPLC) system coupled to an
Agilent 6540 quadrupole time of flight mass spectrometer (Agilent Technologies, Palo Alto, CA, USA)
was applied to obtain the phospholipid profile. An Ascentis Si HPLC Pore column (15 cm × 1.0 mm,
3 µm; Sigma Aldrich, St. Louis, MO, USA) was used for chromatographic separation in gradient mode.
The method was described in details previously [47]. Internal standards PC 14:0/14:0, PI 16:0/16:0,
and PE 14:0/14:0 (Avanti Polar Lipids, Alabaster, AL, USA) were used to confirm the ion variations
observed in the MS spectra. Identification of each phospholipid species was performed according
to the typical fragmentation pathways [48]. The area of each extracted ion chromatogram peak was
normalized to the area of an internal standard to calculate relative abundance of each ion. Detailed
description of the lipidomic methodology is provided in supplementary materials.
4.2.2. Determination of the Activity of Lipid Metabolizing Enzymes
Spectrophotometric method was used to assay phospholipase A2 (PLA2-EC.3.1.1.4) activity using
PLA2 Assay Kit (no. 765021, Cayman Chemical Company, Ann Arbor, MI, USA) according to the kit
instructions [49].
PAF acetylhydrolase (PAF-AH-EC.3.1.1.47) activity was measured spectrophotometrically using
the Cayman’s PAF Acetylhydrolase Assay Kit (no. 760901, Cayman Chemical Company, Ann Arbor,
MI, USA) according to kit instructions [50].
Cyclooxygenase 1 and 2 (COX1/2-EC.1.14.99.1) activities were measured spectrophotometrically
using a commercial assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) [51]. For distinguishing
COX1 activity from COX2 activity the specific COX1 inhibitor SC-560 was used [52].
Int. J. Mol. Sci. 2019, 20, 4249 11 of 17
4.2.3. 4-HNE Determination
Gas chromatography-mass spectrometry (GC/MS) using the selected ion monitoring (SIM) mode,
as the O-PFB-oxime-TMS derivatives, using minor modifications of the method of Luo [53] was used to
measure product of phospholipid fragmentation—4-HNE. Transitions of the precursor to the product
ion were as follows: m/z 333.0 and 181.0 for 4-HNE-PFB-TMS and m/z 307 for IS (benzaldehyde-D6+)
derivative. (7890A GC-7000 quadrupole MS/MS, Agilent Technologies, Palo Alto, CA, USA).
4.2.4. 4-HNE-Protein Adducts Determination
The 4-HNE-protein adducts level was measured using ELISA method using anti-4-HNE-His
murine monoclonal antibody (genuine anti-4-HNE-Hismurine monoclonal antibody, clone 4-HNE 1g4)
and goat anti-mouse antibody (Dako, Carpinteria, CA, USA) as primary and secondary antibodies [54].
Results were shown as a percentage of the expression determined in control cells.
4.2.5. 8-isoPGF2α Determination
LC-MS/MS method of Coolen [55] was used to determination of phospholipid oxidative cyclisation
product, 8-isoPGF2α, which was analyzed in negative-ion mode using MRM mode: m/z 353.2→193.1
(for 8-isoPGF2α) and 357.2→197.1 (for 8-isoPGF2α-d4 used as an internal standard) (LCMS 8060,
Shimadzu, Kyoto, Japan).
4.2.6. Determination of Endocannabinoids and Enzymes Them Degradation
The LC-MS/MS method was used for the quantification of the endocannabinoids level [56].
Endocannabinoids were analyzed in positive-ion mode using MRM mode. Transitions of the
precursors to the product ions were as follows: m/z 348.0→62.15 for AEA, m/z 379.0→269.35
for 2-AG, m/z 356.0→63.05 for AEA-d8, m/z 387.0→294.0 m/z for 2-AG-d8, m/z 430.0→66.0 for
OEA-d4, m/z 324.0→62.0 for LEA, m/z 355.0→263.0 for 2-LG, 326.0→62.0 for OEA. (LCMS 8060,
Shimadzu, Kyoto, Japan). Results were expressed as amount of cannabinoids per mg of protein.
The Siegmund procedure [57] was used to determine FAAH (EC.3.5.1.99) activity, following the releasing
of m-nitroaniline (m-NA) from decanoyl m-nitroaniline at 410 nm. Enzyme activity was expressed as
the amount of enzyme metabolizing 1 pmol of substrat per minute per mg of protein. Releasing of
5’-thio-2-nitrobenzoic acid from arachidonoyl-1-thio-glycerol was used to spectrophotometric [340 nm]
determination of MAGL (EC.3.1.1.23) activity [58]. Enzyme activity was expressed as the amount of
enzyme metabolizing 1 pmol of substrate per minute per mg of protein.
4.2.7. Lipid Mediators Determination
Lipid mediators levels: TXB2, PGE1, 15d-PGJ2, 13-HODE, LTB4, and 15-HETE were estimated
using ultra-performing liquid chromatography tandem mass spectrometry (LCMS 8060, Shimadzu,
Kyoto, Japan) [59]. 15-HETE-d8, LTB4-d4, PGF2α-d4 and PGD2-d4 were used as internal standards for
quantification. Lipid mediators were extracted using SPE and analyzed in negative-ion mode (MRM).
The precursor to the product ion transition was as follows: m/z 369.3→169.1 for TXB2, m/z 353.3→317.2
for PGE1, 315.2→271.2 for 15-d-PGJ2, m/z 295→277 for 13-HODE, and m/z 319→301.2 for 15-HETE.
4.2.8. Proteins Examination
Western blot analysis of protein expression was performed according to Eissa and Seada [60].
Samples were electrophoretically separated on 10% gels, transferred to 0.2 µm pore-sized nitrocellulose,
and incubated overnight with primary antibodies against: GPR55, PPARα (host: rabbit) β-actin (host:
mouse) that were purchased from Sigma-Aldrich, (St. Louis, MO, USA). Primary antibodies against:
Il-10 (host mouse), CB1, CB2, TRPV1 (host rabbit) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Primary antibodies against PPARγ (host: rat) were purchased from Abcam
(Cambridge, UK). Primary antibodies against PPARδ were purchased from Invitrogen (Carlsbad,
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CA, USA). Primary antibodies against IL-2 (host: rat) were purchased from Thermo Fisher Scientific
(Thermo Fisher Scientific, Waltham, MA, USA). Next membranes were incubated for 2 h with alkaline
phosphatase secondary IgG antibody against corresponding primary antibody (Sigma-Aldrich, St. Louis,
MO, USA). Protein bands were visualized using the BCIP/NBT Liquid substrate system (Sigma-Aldrich,
St. Louis, MO, USA). To compare the proteins expression between samples, each band intensity was
estimated using VersaDoc System and Quantity One software (Bio-Rad Laboratories Inc., Hercules,
CA, USA). The results are expressed as a percentage of the expression determined in the control cells.
4.3. Statistical analysis
All data were expressed as mean ± SD. For data analysis program Statistica (Statistica 13.3, StatSoft
Polska, Cracow, Poland) were used. These data were analyzed using one-way analysis of variance
followed by a post hoc Tukey test. Values of p < 0.05 were considered significant.
5. Conclusions
In conclusion, the results of our research suggest that the development of both forms of psoriasis
is strongly associated with oxidative stress resulting in altered lipid metabolism and cytokine
production, leading to the development of pro-inflammatory preconditioning of the immune cells.
In such a vicious circle, mononuclear cells additionally activate pro-inflammatory states and enhance
pro-oxidative, stressful conditions. Thus, ROS and enzyme-dependent changes in mononuclear cell
phospholipids can be considered as important processes associated with the pathophysiology of
psoriasis. Moreover, the reduced expression of endocannabinoid receptors in PsA suggests the failure
of the anti-inflammatory mechanism and may be an important factor leading to the transformation of
Ps into a more severe form of PsA. Finally, we assume that monitoring the level of 4-HNE adducts can
help predict the progression of Ps into PsA if done complementary to the other parameters of lipid
metabolism and the levels of respective cytokines that should be analyzed in further studies.
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Abbreviations
2-AG 2-Arachidonylglycerol
2-LG 2-Linoleoylglycerol
4-HNE 4-Hydroxynonenal
4-ONE 4-Oxynonenal
8-isoPGF2α 8-iso prostaglandin F2α
13-HODE 13-hydroxyoctadecadienoic acid
15-HETE 15-Hydroxyeicosatetraenoic acid
15d-PGJ2 15-deoxy-∆12,14-prostaglandin J2
AEA Anandamide
AIDS Acquired immunodeficiency syndrome
CB Cannabinoid receptor
COX Cyclooxygenase
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EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-linked immunosorbent assay
ERK5 Extracellular-signal-regulated kinase 5
FAAH Fatty acid amide hydrolase
GC Gas chromatography
GPR55 G protein-coupled receptor 55
HILIC Hydrophilic interaction chromatography
HPLC High-performance liquid chromatography
IFNγ Interferon γ
IKK IκB kinase
IL Interleukin
IMQ Imiquimod
LC Liquid chromatography
LEA Dihomo-γ-linolenoylethanolamine
LOX Lipoxygenases
LPC Lysophosphatidylcholine
LTB4 Leukotriene B4
MAGL Monoacylglycerol lipase
MS Mass spectrometry
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells
NOX NADPH oxidase
Ns Not significant
OEA Oleoylethanolamide
PAF-AH Platelet-activating factor acetylhydrolase
PBS Phosphate-buffered saline
PC Phosphatidylcholine
PCA Principal component analysis
PGE1 Prostaglandin E1
PI Phosphatidylinositol
PLA2 Phospholipase A2
PLS-DA partial least squares-discriminate analysis
PPAR Peroxisome proliferator-activated receptor
Ps Psoriasis vulgaris
PsA Psoriatic arthritis
PUFAs Polyunsaturated fatty acids
ROS Reactive oxygen species
RT Retention time
SIM Selected ion monitoring
SLE Systemic lupus erythematosus
SM Sphingomyelin
Th T helper lymphocytes
TNFα Tumor necrosis factor α
TNFR Tumor necrosis factor receptor
TRPV1 The transient receptor potential cation channel subfamily V member 1
TxA2 Thromboxane A2
TxB2 Thromboxane B2
UPLC Ultra-performance liquid chromatography
VIP variable importance in projection
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